Thus, by disrupting with the SIRP-α-CD47 axis (e.g., by using antibodies against SIRPα and CD47), it is possible to restore recognition and phagocytosis of tumor cells by TAMs, and to activate anti-tumor immune responses [107,109]. Here, SIRPA is linked to neoplasm.